Author: De Jong, Cornelis N.; Saes, Lotte; Klerk, Clara P. W.; Van der Klift, Marjolein; Cornelissen, Jan J.; Broers, Annoek E. C.
Title: Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience Document date: 2017_10_26
ID: 1hcp36cw_26
Snippet: Acute GVHD is an important cause of morbidity and mortality following alloSCT. Steroidrefractory acute GVHD in particular is associated with a poor prognosis with a long term overall survival of only 20-30%. Studies evaluating second-line treatment with the anti-TFNα agent etanercept have shown promising results with overall response rates of 50-80% [8] [9] [10] ......
Document: Acute GVHD is an important cause of morbidity and mortality following alloSCT. Steroidrefractory acute GVHD in particular is associated with a poor prognosis with a long term overall survival of only 20-30%. Studies evaluating second-line treatment with the anti-TFNα agent etanercept have shown promising results with overall response rates of 50-80% [8] [9] [10] .
Search related documents:
Co phrase search for related documents- important cause and mortality morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- important cause and poor prognosis: 1, 2, 3, 4, 5
- important cause and response rate: 1, 2
- important cause and second line: 1
- important cause and second line treatment: 1
- long term and mortality morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and overall survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and promising result: 1, 2, 3, 4, 5
- long term and response rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- long term and second line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- long term and second line treatment: 1, 2, 3, 4, 5, 6
- mortality morbidity and overall survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- mortality morbidity and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- mortality morbidity and promising result: 1
- mortality morbidity and response rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- mortality morbidity and second line: 1, 2, 3, 4, 5, 6, 7, 8
- mortality morbidity and second line treatment: 1, 2
- overall survival and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date